Pyridoxine is currently used in the treatment of PH1 as it is able to rescue the effect of misfolding mutations of AGT, though its effectivity is only associated to certain folding-defective AGT variants [31,32]. The gene discussed is AGT; the disease is primary hyperoxaluria type 1.